Biolase, Inc. (BIOL): Price and Financial Metrics
BIOL Price/Volume Stats
Current price | $0.14 | 52-week high | $47.10 |
Prev. close | $0.14 | 52-week low | $0.13 |
Day low | $0.13 | Volume | 1,807,400 |
Day high | $0.14 | Avg. volume | 2,567,332 |
50-day MA | $0.50 | Dividend yield | N/A |
200-day MA | $3.08 | Market Cap | 4.34M |
BIOL Stock Price Chart Interactive Chart >
BIOL POWR Grades
- BIOL scores best on the Growth dimension, with a Growth rank ahead of 85.72% of US stocks.
- BIOL's strongest trending metric is Quality; it's been moving up over the last 156 days.
- BIOL ranks lowest in Momentum; there it ranks in the 4th percentile.
BIOL Stock Summary
- The capital turnover (annual revenue relative to shareholder's equity) for BIOL is 149.77 -- better than 99.78% of US stocks.
- BIOL's price/sales ratio is 0.05; that's higher than the P/S ratio of merely 0.87% of US stocks.
- In terms of volatility of its share price, BIOL is more volatile than 99.08% of stocks we're observing.
- Stocks that are quantitatively similar to BIOL, based on their financial statements, market capitalization, and price volatility, are EZFL, NSP, GAN, CAPL, and XERS.
- BIOL's SEC filings can be seen here. And to visit BIOLASE INC's official web site, go to www.biolase.com.
BIOL Valuation Summary
- In comparison to the median Healthcare stock, BIOL's EV/EBIT ratio is 103.42% lower, now standing at -0.5.
- Over the past 243 months, BIOL's EV/EBIT ratio has gone down 81.1.
Below are key valuation metrics over time for BIOL.
Stock | Date | P/S | P/B | P/E | EV/EBIT |
---|---|---|---|---|---|
BIOL | 2023-12-29 | 0.1 | 7.8 | -0.1 | -0.5 |
BIOL | 2023-12-28 | 0.1 | 8.4 | -0.1 | -0.5 |
BIOL | 2023-12-27 | 0.1 | 8.1 | -0.1 | -0.5 |
BIOL | 2023-12-26 | 0.1 | 8.1 | -0.1 | -0.5 |
BIOL | 2023-12-22 | 0.1 | 8.1 | -0.1 | -0.5 |
BIOL | 2023-12-21 | 0.1 | 7.8 | -0.1 | -0.5 |
BIOL Growth Metrics
- Its year over year cash and equivalents growth rate is now at -46.87%.
- Its 4 year cash and equivalents growth rate is now at -52.36%.
- Its 2 year price growth rate is now at -64.92%.
The table below shows BIOL's growth in key financial areas (numbers in millions of US dollars).
Date | Revenue | Operating Cash Flow | Net Income to Common Stock |
---|---|---|---|
2022-09-30 | 46.819 | -24.283 | -24.27 |
2022-06-30 | 44.34 | -21.335 | -19.168 |
2022-03-31 | 41.239 | -18.232 | -14.265 |
2021-12-31 | 39.188 | -16.71 | -16.704 |
2021-09-30 | 35.301 | -14.954 | -17.568 |
2021-06-30 | 32.309 | -13.464 | -31.649 |
BIOL's Quality Factors
The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.- BIOL has a Quality Grade of D, ranking ahead of 22.41% of graded US stocks.
- BIOL's asset turnover comes in at 0.622 -- ranking 67th of 186 Medical Equipment stocks.
- TCMD, XENT, and MSA are the stocks whose asset turnover ratios are most correlated with BIOL.
The table below shows BIOL's key quality metrics over time.
Period | Asset Turnover | Gross Margin | ROIC |
---|---|---|---|
2021-06-30 | 0.622 | 0.330 | -0.489 |
2021-03-31 | 0.599 | 0.290 | -0.720 |
2020-12-31 | 0.673 | 0.271 | -0.847 |
2020-09-30 | 0.775 | 0.368 | -0.933 |
2020-06-30 | 0.945 | 0.365 | -1.223 |
2020-03-31 | 1.103 | 0.376 | -0.989 |
BIOL Price Target
For more insight on analysts targets of BIOL, see our BIOL price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.
Average Price Target | $2.25 | Average Broker Recommendation | 1.38 (Strong Buy) |
Biolase, Inc. (BIOL) Company Bio
BIOLASE, Inc.,a medical device company, develops, manufactures, and markets laser systems in dentistry and medicine in the United States and internationally. It offers Waterlase dental laser systems for cutting soft and hard tissue; and diode laser systems, which are used in soft tissue, pain therapy, and cosmetic procedures, such as teeth whitening. The company was founded in 1984 and is based in Irvine, California.
Latest BIOL News From Around the Web
Below are the latest news stories about BIOLASE INC that investors may wish to consider to help them evaluate BIOL as an investment opportunity.
BIOLASE RECEIVES TOP WORKPLACES 2023 AWARDBIOLASE, Inc. (NASDAQ: BIOL), the global leader in dental lasers, today announced it has been awarded a Top Workplaces 2023 honor by Orange County Register Top Workplaces. The award is based solely on employee feedback gathered through a third-party survey administered by employee engagement technology partner Energage LLC. The confidential survey uniquely measures 15 culture drivers that are critical to success, including alignment, execution, and connection. |
BIOLASE Successfully Concludes Waterlase iPlus All Tissue Laser TrialBIOLASE, Inc. (NASDAQ: BIOL), the global leader in dental lasers, today announced the successful completion of a trial program featuring the Waterlase iPlus All Tissue laser conducted by six leading U.S. dentists. The trial, led by an independent consultant, evaluated both the potential return on investment (ROI) and clinical adoption of BIOLASE's leading technology. The trial revealed unanimous doctor satisfaction with the performance and desire to recommend the purchase to others. This represe |
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on FridayIt's time to start the final day of trading this week with a breakdown of the biggest pre-market stock movers for Friday! |
BIOLASE, Inc. Announces Pricing of $1.4 Million Registered Direct Offering Priced At-the-Market Under Nasdaq RulesBIOLASE, Inc. (NASDAQ: BIOL), the global leader in dental lasers, announced today that it has entered into a securities purchase agreement with a single institutional investor to purchase approximately $1.4 million of its common stock and pre-funded warrants in a registered direct offering and warrants to purchase common stock in a concurrent private placement, priced at-the-market under Nasdaq rules. The combined effective purchase price for one share of common stock (or pre-funded warrant in l |
BIOLASE REPORTS THIRD QUARTER FINANCIAL RESULTS; COMPANY BENEFITTING FROM STRATEGIC ACTIONS TAKEN TO STREAMLINE OPERATIONS AND GAIN GREATER OPERATIONAL EFFICIENCIESBIOLASE, Inc. (NASDAQ: BIOL), the global leader in dental lasers, today announced its financial results for the third quarter ended September 30, 2023. |
BIOL Price Returns
1-mo | -5.41% |
3-mo | -87.61% |
6-mo | -91.95% |
1-year | -99.59% |
3-year | -99.99% |
5-year | -100.00% |
YTD | -87.52% |
2023 | -98.27% |
2022 | -93.33% |
2021 | -6.41% |
2020 | -24.61% |
2019 | -44.17% |
Continue Researching BIOL
Want to see what other sources are saying about Biolase Inc's financials and stock price? Try the links below:Biolase Inc (BIOL) Stock Price | Nasdaq
Biolase Inc (BIOL) Stock Quote, History and News - Yahoo Finance
Biolase Inc (BIOL) Stock Price and Basic Information | MarketWatch
Loading social stream, please wait...